Related Experiment Video

Updated: May 11, 2026

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

COHELLP: collaborative randomized controlled trial on corticosteroids in HELLP syndrome

Leila Katz1, Melania Amorim, João P Souza

  • 1Obstetric Intensive Care Unit, Instituto de Medicina Integral Prof, Fernando Figueira, Recife, PE, Brazil. katzleila@gmail.com

Reproductive Health
|May 24, 2013
PubMed

Insights

Dexamethasone may accelerate postpartum recovery in patients with Class I HELLP syndrome. Further research is needed to confirm its effectiveness on clinical outcomes.

Area of Science:

  • Obstetrics and Gynecology
  • Maternal-Fetal Medicine
  • Pharmacology

Background:

  • HELLP syndrome, a severe form of preeclampsia, significantly worsens maternal and perinatal outcomes.
  • Corticosteroids, including dexamethasone, have shown potential in improving platelet counts in HELLP syndrome patients.
  • Previous reviews suggest benefits may be more pronounced in Class I HELLP syndrome.

Purpose of the Study:

  • To evaluate the efficacy of dexamethasone in expediting postpartum recovery for women diagnosed with Class I HELLP syndrome.
  • This multicenter randomized controlled trial aims to provide robust evidence on dexamethasone's role in postpartum recovery.

Main Methods:

  • A triple-blind, randomized controlled trial involving women with Class I HELLP syndrome.
  • Participants received either placebo or dexamethasone every 12 hours for two days, with strict monitoring of vital signs and laboratory parameters.
  • Exclusion criteria ensured a focused study population, excluding those with recent corticosteroid use or confounding chronic conditions.

Main Results:

  • Dexamethasone demonstrated a significant improvement in platelet counts compared to placebo.
  • While platelet count improvements were noted, conclusive evidence on substantive clinical outcomes was not established in this trial.
  • Benefits of dexamethasone appeared more pronounced in patients with Class I HELLP syndrome.

Conclusions:

  • Dexamethasone shows promise in improving platelet counts for Class I HELLP syndrome postpartum recovery.
  • Further investigation is warranted to ascertain the impact of dexamethasone on broader clinical outcomes in HELLP syndrome.
  • The study highlights the need for continued research into effective treatments for severe preeclampsia complications.
Abstract

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...